Table 3.

Mean change in weight and other outcomes between baseline and 12-week follow-up within olanzapine (n = 18).

	Baseline		12-week		Paired t test		Generalised estimating equations
	Mean	SD	Mean	SD	Mean change	p value a	β	95% CI Lower	95% CI Upper	p value b
Weight (kg)	81.56	16.58	81.99	17.62	0.43	0.352	0.43	−0.42	1.28	0.325
BMI (kg/m2)	30.24	4.21	30.31	4.44	−0.07	0.695	0.07	−0.27	0.42	0.681
Waist circumference (cm)	97.94	9.52	98.67	11.06	0.73	0.530	0.73	−1.44	2.89	0.510
Metabolic parameters
Fasting glucose (mmol/L)	4.95	0.38	5.10	0.53	0.15	0.247	0.15	−0.09	0.39	0.217
HbA1c (%)	5.54	0.38	5.53	0.44	−0.01	0.926	−0.01	−0.12	0.11	0.922
Cholesterol (mmol/L)	5.12	1.16	4.94	1.15	−0.18	0.167	−0.18	−0.41	0.06	0.138
HDL (mmol/L)	1.19	0.26	3.06	0.92	0.05	0.105	0.05	−0.01	0.11	0.079
LDL (mmol/L)	3.13	0.92	1.24	0.30	−0.07	0.491	−0.07	−0.27	0.13	0.469
Triglycerides (mmol/L)	1.77	0.81	1.43	0.59	−0.34	0.006	−0.34	−0.55	−0.14	0.001
Neurocognition tests
Symbol coding	45.94	10.23	47.83	10.61	1.89	0.302	1.89	−1.49	5.27	0.273
Digit span	16.83	4.16	16.39	3.50	−0.44	0.420	−0.44	−1.47	0.58	0.395
Clinical scales
GAF total	69.11	7.44	73.44	7.51	4.33	0.030	4.33	0.85	7.82	0.015
CGI-S	2.11	0.47	2.17	0.71	0.06	0.749	0.06	−0.27	0.38	0.738
CGI-I	2.00	0.50	1.94	0.80	0.00	1.000	−0.02	−0.30	0.27	0.914
PANSS total	46.89	9.47	47.89	9.69	1.00	0.627	1.00	−2.85	4.85	0.611
WHODAS	23.06	9.14	22.35	10.65	0.12	0.948	−0.05	−3.42	3.32	0.977

β: beta coefficient; CI: confidence interval; BMI: body mass index; HbA1c: haemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; GAF: Global Assessment of Functioning; CGI-S: Clinical Global Impression–Severity; CGI-I: Clinical Global Impression–Improvement; PANSS: Positive and Negative Syndrome Scale; WHODAS: World Health Organization Disability Assessment Scale.

^aPaired t test.

^bAge, sex, dosage and baseline measurements as covariates.

Bold values denote statistical significance at the p < 0.05